BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hayes MJ, Stein AC, Sakuraba A. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis: Combination therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1177-85. [DOI: 10.1111/jgh.12517] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Fiorino G, Danese S, Giacobazzi G, Spinelli A. Medical therapy versus surgery in moderate-to-severe ulcerative colitis. Digestive and Liver Disease 2021;53:403-8. [DOI: 10.1016/j.dld.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Parrish RH. Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary. Gastroenterology Insights 2021;12:293-301. [DOI: 10.3390/gastroent12030026] [Reference Citation Analysis]
3 Cantarini L, Lopalco G, Vitale A, Caso F, Lapadula G, Iannone F, Galeazzi M, Rigante D. Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant. Int J Rheum Dis 2015;18:473-5. [PMID: 25522898 DOI: 10.1111/1756-185X.12521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Gorovits B, Baltrukonis DJ, Bhattacharya I, Birchler MA, Finco D, Sikkema D, Vincent MS, Lula S, Marshall L, Hickling TP. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol 2018;192:348-65. [PMID: 29431871 DOI: 10.1111/cei.13112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
5 Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017;15:229-239.e5. [PMID: 27639327 DOI: 10.1016/j.cgh.2016.08.044] [Cited by in Crossref: 90] [Cited by in F6Publishing: 73] [Article Influence: 15.0] [Reference Citation Analysis]
6 Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537-545. [PMID: 26284562 DOI: 10.1038/nrgastro.2015.135] [Cited by in Crossref: 164] [Cited by in F6Publishing: 157] [Article Influence: 23.4] [Reference Citation Analysis]
7 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 451] [Article Influence: 205.7] [Reference Citation Analysis]
8 Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs 2017;31:299-316. [PMID: 28612180 DOI: 10.1007/s40259-017-0231-8] [Cited by in Crossref: 131] [Cited by in F6Publishing: 111] [Article Influence: 32.8] [Reference Citation Analysis]
9 Elias ED, Targownik LE, Singh H, Bernstein CN. A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD. Inflamm Bowel Dis 2020;26:150-7. [PMID: 31340002 DOI: 10.1093/ibd/izz148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Dénarié D, Rinaudo-Gaujous M, Thomas T, Paul S, Marotte H. Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab. Mediators Inflamm 2017;2017:3708250. [PMID: 28352145 DOI: 10.1155/2017/3708250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Yokoyama Y, Sawada K, Aoyama N, Yoshimura N, Sako M, Hirai F, Kashiwagi N, Suzuki Y. Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients With Inflammatory Bowel Disease Showing Lost Response to Infliximab. J Crohns Colitis. 2020;14:1264-1273. [PMID: 32166331 DOI: 10.1093/ecco-jcc/jjaa051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
12 Day AS, Gulati AS, Patel N, Boyle B, Park KT, Saeed SA. The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:361-8. [PMID: 29210919 DOI: 10.1097/MPG.0000000000001850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yokoyama Y, Kamikozuru K, Watanabe K, Nakamura S. Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte/monocyte apheresis: A case series. Cytokine 2018;103:25-8. [DOI: 10.1016/j.cyto.2017.12.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
15 Privitera G, Pugliese D, Onali S, Petito V, Scaldaferri F, Gasbarrini A, Danese S, Armuzzi A. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmun Rev 2021;20:102832. [PMID: 33866066 DOI: 10.1016/j.autrev.2021.102832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Cozijnsen MA, Escher JC, Griffiths A, Turner D, de Ridder L. Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:951-961. [PMID: 25723615 DOI: 10.1097/mib.0000000000000245] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
17 Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;45:1043-57. [PMID: 28239873 DOI: 10.1111/apt.13990] [Cited by in Crossref: 71] [Cited by in F6Publishing: 50] [Article Influence: 14.2] [Reference Citation Analysis]
18 Fernández-salazar L, Muñoz F, Barrio J, Muñoz C, Pajares R, Rivero M, Prieto V, Legido J, Bouhmidi A, Herranz M, Fernández N, Sánchez-ocaña R, Joao D, Santos F. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study). Scandinavian Journal of Gastroenterology 2015;51:186-95. [DOI: 10.3109/00365521.2015.1070900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Wang Y, MacDonald JK, Vandermeer B, Griffiths AM, El-Matary W. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;CD007560. [PMID: 26263042 DOI: 10.1002/14651858.cd007560.pub3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
20 García-Bosch O, Aceituno M, Ordás I, Etchevers J, Sans M, Feu F, Panés J, Ricart E. Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response-An Observational Study. Dig Dis Sci 2016;61:2051-9. [PMID: 26921082 DOI: 10.1007/s10620-016-4089-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
21 Chande N, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;CD006618. [PMID: 25162749 DOI: 10.1002/14651858.cd006618.pub3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
22 Pecoraro V, De Santis E, Melegari A, Trenti T. The impact of immunogenicity of TNFα inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis. Autoimmun Rev 2017;16:564-75. [PMID: 28411169 DOI: 10.1016/j.autrev.2017.04.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
23 Yoshimura N, Yokoyama Y, Sako M, Aoyama N, Hirai F, Sawada K, Kashiwagi N, Suzuki Y. Development of a C1q-immobilized (Cim) assay to measure total antibodies to infliximab and its clinical relevance in patients with inflammatory bowel disease. Cytokine 2019;120:54-61. [DOI: 10.1016/j.cyto.2019.02.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 Komaki Y, Komaki F, Sakuraba A, Cohen R. Approach to Optimize Anti-TNF-α Therapy in Patients With IBD. Curr Treat Options Gastroenterol. 2016;14:83-90. [PMID: 26872815 DOI: 10.1007/s11938-016-0079-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]